Live
FierceBiotechKardigan buttons up $400M upsized IPO to power heart drugs toward phase 3FierceBiotechNovocure device fails to improve brain cancer patients’ survival in phase 3 testFierceBiotechNortiva purrs into action with long-acting Lynx platform salvaged from Langer startupEndpoints NewsInnoviva revives Lyndra's long-acting oral drug platformFierceBiotechBiogen inks $1B RayThera buyout to bag preclinical immunology assetsEndpoints NewsModerna adds commercial chief, expands Stephen Hoge's role; Reunion Neuroscience CEO departsEndpoints NewsEli Lilly's TuneLab hits 100 members, adding Chai's AI modelsCellChloroplast sunscreening by protein condensates confers high-light toleranceFierceBiotechF2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 testEndpoints NewsAntifungal from F2G, Shionogi succeeds in Phase 3 studyRoche MediaPartnering for Sustainable Healthcare: Roche Stands with Taiwan to Build an Innovation-Friendly Biomedical Ecosystem - Taiwan Business TOPICSBioPharma DiveKardigan extends biotech’s streak of big IPOs with $400M haul
Illumina Jan 25, 2026

Wealth Enhancement Advisory Services LLC Buys 9,997 Shares of Illumina, Inc. $ILMN - MarketBeat

Wealth Enhancement Advisory Services LLC Buys 9,997 Shares of Illumina, Inc. $ILMN - MarketBeat

Original
Body unavailable. Use the original source.